GlaxoSmithKline PLC
LSE:GSK
GlaxoSmithKline PLC
LSE:GSK
Price:
1 711 GBX
0.35%
Updated:
May 2, 2024
GlaxoSmithKline PLC
Cash from Operating Activities
|
GlaxoSmithKline PLC
Cash from Operating Activities Peer Comparison
Comparables:
AZN
VRNA
INDV
HIK
DPH
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Operating Activities
£6.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Operating Activities
$10.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
32%
|
CAGR 10-Years
3%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Operating Activities
-$50.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Operating Activities
-$315m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Operating Activities
$608m
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Operating Activities
£63.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
See Also
What is GlaxoSmithKline PLC's Cash from Operating Activities?
Cash from Operating Activities
6.8B
GBP
6.8B
GBP
Based on the financial report for Dec 31, 2023, GlaxoSmithKline PLC's Cash from Operating Activities amounts to 6.8B GBP.
What is GlaxoSmithKline PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-1%
-1%
Over the last year, the Cash from Operating Activities growth was -9%. The average annual Cash from Operating Activities growth rates for GlaxoSmithKline PLC have been -7% over the past three years , -4% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
